Abzena appoints Kevin Lundquist as Chief Financial Officer

01st February 2022

Cambridge, UK and San Diego, CA, February 1, 2022 – Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Kevin Lundquist as Chief Financial Officer, effective January 31, 2022.

Richard Milbank, our former Chief Financial Officer, will advise and remain with the Company until 31 March 2022. Richard has made a significant contribution to Abzena during the last 4 years, building a strong financial infrastructure and team that will position us for continued success, especially within Abzena (Cambridge) where he has been based during COVID. We have mutually agreed it is the right time for Abzena to appoint a US based Chief Financial Officer to take us through the next stage of our growth plans.  

Mr. Lundquist joins us with 25 years in the financial industry, starting at Abbott Laboratories.   He held various positions of increasing seniority at Caterpillar, Inc. culminating to the Chief Financial Officer for the Caterpillar Japan Division in Tokyo.  He later joined Oracle and then Genentech/Roche where he was the Senior Director Finance, Global Drug Substance Manufacturing Operations.   Mr. Lundquist has been the Vice President of Finance of Revance Therapeutics for the past two years. 

Mr. Lundquist is a global and strategic financial executive within the pharmaceutical, medical device, heavy machinery, and technology sectors.  He has managed FP&A activities, developed organizations, and driven strategic and tactical initiatives across organizations. 


Dr. Jonathan Goldman MD, CEO of Abzena commented, “We are pleased to welcome Kevin to Abzena.  Based in the US, he brings a wealth of financial and strategic experience which will be valuable as we continue our growth across all sites and as we build out our new $200m GMP manufacturing site in North Carolina this year.  Abzena is the only organization able to deliver fully integrated gene to GMP in biologics, complex large molecules, and ADC under one roof.  We have shown great success in transitioning complex molecules through lead selection into clinical development in multiple therapeutic areas.  We are very fortunate to have Kevin join our team.”

Mr. Lundquist stated, “I am pleased to have the opportunity to support Abzena’s continued growth and success.  Abzena’s strong track record in integrated development positions the company well as the world’s premier partner research organization”.

Mr. Lundquist has his Bachelor of Science in Accounting and Finance from the University of Utah and his Master’s Degree in Business Administration (MBA) from Utah State University.   


Additionally, Kevin is the Chairman of the Board for California Re-entry Program in San Francisco which works with incarcerated inmates and the department of corrections to bring educational and rehabilitative programs to inmates. He is also a member of the Search and Rescue K9 Team in Marin County and Yosemite National Park.  


About Abzena

Abzena is a leading partner research organization which offers discovery, design, development and cGMP manufacture of biologics, bioconjugates and complex or highly potent small molecules to the global biopharmaceutical industry. From its facilities in the UK and US the company provides its customers with concept to clinic solutions. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.